119 related articles for article (PubMed ID: 1371604)
1. [Cancer of the breast in young women: should chemotherapy be intensified?].
Piccart MJ
Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
[No Abstract] [Full Text] [Related]
2. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
3. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
4. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
6. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
7. Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity.
Jenkins P; Wallis R
J Oncol Pharm Pract; 2010 Dec; 16(4):251-5. PubMed ID: 19965948
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
11. [Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)].
Perez Carrion R; Jimeno JM; Jimenez V; Guardiola L; Donnay O; Sanchez J
Bull Cancer; 1990; 77(10):1033-5. PubMed ID: 2249014
[No Abstract] [Full Text] [Related]
12. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
13. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
14. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Kennedy MJ; Donehower RC; Rowinsky EK
Semin Oncol; 1995 Aug; 22(4 Suppl 8):23-7. PubMed ID: 7543700
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
Chow LW; Day W; Ng KC
Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
[TBL] [Abstract][Full Text] [Related]
18. Can granulocyte-colony stimulating factor worsen anemia?
Dang C; Hudis C
J Clin Oncol; 2006 Jul; 24(19):2985-6. PubMed ID: 16769981
[No Abstract] [Full Text] [Related]
19. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Ries F; Duhem C; Kleiber K; Dicato M
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
[TBL] [Abstract][Full Text] [Related]
20. [Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].
Konecny G; Nestle-Krämling C; Untch M
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():301-2. PubMed ID: 7509677
[No Abstract] [Full Text] [Related]
[Next] [New Search]